Lead Product(s) : Pimodivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Janssen to Discontinue Pimodivir Influenza Development Program
Details : Results from pre-planned interim analyses of the Phase 3 pimodivir trial in hospitalised influenza A patients indicate pimodivir in conjunction with the standard of care is unlikely to demonstrate additional benefit in hospitalised influenza A patients c...
Brand Name : JNJ-63623872
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 02, 2020
Lead Product(s) : Pimodivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?